Compare Cytokinetics Inc (CYTK) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Docusign Inc — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Docusign Inc trades at $71.13 (market cap $13.35B). The key difference: Docusign Inc is the larger of the two by market cap, and Docusign Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Docusign Inc for 71 Days on average.
| CYTK | DOCU | |
|---|---|---|
Market Cap | $8.62B | $13.35B |
Volume | 2,594,626 | 3,158,858 |
Sector | Health | Technology |
52-Week High | $87.26 | $73.14 |
52-Week Low | $54.76 | $41.75 |
Typical Hold Time | 19 Days | 71 Days |
Enterprise Value | $8.72B | $12.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
DOCU trades at $70.08, up 1.71% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.98 billion in 2025, with net income surging to $1.07 billion, though cash flow turned negative. Recent news highlights AI integration in contract processing and leadership in workflow software.
Outlook remains positive with continued earnings momentum and AI-driven growth, but risks include insider selling and competitive pressures. The stock offers growth potential but requires monitoring of cash flow trends and market saturation in e-signature adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
